CHGCY · Healthcare
Chugai Pharmaceutical Co., Ltd.
Market cap
$74.5B
Industry
Drug Manufacturers - General
Sector
Healthcare
Exchange
OTC Markets OTCPK
About Chugai Pharmaceutical Co., Ltd.
Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. It offers oncology products, such as Alecensa, Avastin, FoundationOne, Herceptin, Kadcyla, Lunsumio, Perjeta, Phesgo, Polivy, and Tecentriq; Actemra for humanized anti-human IL-6 receptor monoclonal antibody; CellCept, an immunosuppressant; Enspryng, a pH-dependent binding humanized anti-IL-6 receptor monoclonal antibody; Evrysdi, a spinal muscular atrophy agent; Hemlibra, an anti-coagulation…
Not in our coverage. Chugai Pharmaceutical Co., Ltd. isn't currently held by any of the 50 hedge funds we track. The price chart and company profile below come from public Yahoo Finance data.
Price History
Loading price data...
Return:
High:
Low:
⚠ Disclaimer: This page is for informational purposes only. Holdings data from SEC EDGAR 13F filings, delayed up to 135 days. Not a recommendation to buy or sell Chugai Pharmaceutical Co., Ltd. or any security.
订阅每周更新
我们每周会把巴菲特、达利欧、阿克曼以及另外 47 位传奇投资人正在买入的股票发送给你 — 免费,直接来自他们的 SEC 申报文件。
永久免费 · 无垃圾邮件 · 随时退订